安罗替尼治疗晚期非小细胞肺癌的疗效与安全性的Meta分析

目的:采用Meta分析方法对安罗替尼治疗晚期非小细胞肺癌疗效与安全性进行系统评价。方法:检索Pubmed、EMbase、Cochrane Library、中国知网、万方、维普和中国生物医学文献数据库，查阅自建库至2020年1月公开发表的研究安罗替尼治疗晚期非小细胞肺癌的文献。按照纳入与排除标准选择文献，质量评估，资料提取，采用RevMan 5.3软件进行Meta分析。结果:共纳入4篇中文RCT文献，均为高质量研究。Meta分析结果显示，安罗替尼治疗晚期非小细胞肺癌的有效率［OR=2.03，95%CI（1.04，3.96），P=0.04］、控制率［OR=7.56，95%CI（5.21，10.97），P＜0.000 01］、无进展生存期［HR=0.26，95%CI（0.21，0.33），P＜0.000 01］和总体生存期［HR=0.72，95%CI（0.58，0.89），P=0.002］均优于安慰剂组。高血压、手足综合征、甲减、咯血和腹泻在安罗替尼组发生率更高（P均<0.05）。结论:安罗替尼可提高晚期非小细胞肺癌的疗效，延长生存期，且安全性可控。

Efficacy and safety of anlotinib in the treatment for advanced non-small cell lung cancer:A Meta-analysis

Objective:To evaluate the efficacy and safety of anlotinib in the treatment for advanced non-small cell lung cancer by Meta-analysis.Methods:Studies were identified by searching Pubmed,EMbase,Cochrane Library,CNKI,Wanfang,VIP and CBM by January 2020.Clinical trials of anlotinib in the treatment for advanced non-small cell lung cancer were included.Choose studies according to the inclusion criteria and exclusion criteria,and evaluate quality retrieve data.Meta-analysis was performed for the results of studies by using RevMan 5.3 software.Results:4 studies were included.They were all high quality studies.The results showed:The effective rate［OR=2.03,95%CI(1.04,3.96),P=0.04］,the response rate［OR=7.56,95%CI(5.21,10.97),P＜0.000 01］,the progression-free survival［HR=0.26,95%CI(0.21,0.33),P＜0.000 01］ and the overall survival［HR=0.72,95%CI(0.58,0.89),P=0.002］ of anlotinib in the treatment for advanced non-small cell lung cancer were significantly superior to placebo.The incidence of hypertension,hand-foot syndrome,hypothyroidism,haemoptysis and diarrhea were higher in the anlotinib(P＜0.05).Conclusion:Anlotinib could improve the efficacy and prolong the survival time of advanced non-small cell lung cancer,and its safety could be in control.